Nrx pharmaceuticals announces expansion of zyesami® (aviptadil) us expanded access and right to try programs for patients with covid-19 respiratory failure who have exhausted all approved treatments

Radnor, pa., jan. 18, 2022 (globe newswire) -- nrx pharmaceuticals (nasdaq: nrxp) today announced enhancements to its expanded access and right to try programs. the programs enable patients with respiratory failure from covid-19, who have tried all approved medicines, including remdesivir, and who are not able to participate in a clinical study, to receive zyesami® (aviptadil) upon a physician's prescription.
NRXP Ratings Summary
NRXP Quant Ranking